ARA-290

The Innate Repair Receptor — A Tissue-Damage-Selective Target#

ARA-290 is an 11-amino-acid peptide modeled on the aqueous-exposed face of helix B of erythropoietin. The design intent was surgical: keep EPO's tissue-protective signaling, discard its erythropoietic activity. It works because EPO actually signals through two different receptors — the classical EPOR homodimer (which drives red blood cell production, raises hematocrit, and carries thrombosis risk) and the proposed Innate Repair Receptor (IRR), a heterocomplex of EPOR and the β-common receptor (CD131). ARA-290 binds the IRR with high affinity and essentially ignores the erythropoietic homodimer.

The elegant part: the IRR is not constitutively expressed on healthy tissue. It is rapidly upregulated at sites of hypoxia, inflammation, or mechanical injury. So the peptide is pharmacologically silent on intact tissue and only activates where damage is already flagging the receptor — a built-in selectivity that explains the unusually clean side-effect profile.

"ARA 290 is a non-erythropoietic peptide that specifically targets the innate repair receptor (IRR), with clinical trials demonstrating improvement in neuropathic pain and small fiber regeneration." — van Velzen M, Heij L, Niesters M, et al. Expert Opinion on Investigational Drugs, 2014

Downstream Signaling — JAK2/STAT3, PI3K/Akt, and Cytokine Suppression#

IRR activation triggers JAK2 phosphorylation, which fans out into STAT3/STAT5, PI3K/Akt, and MAPK cascades. Practically, this produces three outputs the reader cares about:

1. Anti-apoptotic tissue protection in neurons, vascular endothelium, renal tubules, and cardiomyocytes — damaged cells that would otherwise commit to apoptosis are rescued.
2. Strong cytokine suppression — TNF-α, IL-6, and other pro-inflammatory signals are knocked down locally, and macrophages polarize away from the M1 inflammatory phenotype toward reparative M2.
3. Promotion of small-fiber nerve regeneration — re-innervation of epidermal and corneal nerve fibers is measurable on confocal microscopy after 4–8 weeks of daily administration.

"Stimulation of the IRR by pHBSP strongly suppressed inflammatory cytokine release and protected microvascular integrity without increasing red blood cell parameters." — Dennhardt S, Pirschel W, Wissuwa B, et al. Frontiers in Immunology, 2022

This is the mechanistic rationale for stacking ARA-290 alongside BPC-157 and TB-500 in tendon and nerve-entrapment protocols: BPC and TB-500 handle the structural/angiogenic half, ARA-290 handles the neuropathic-pain and inflammatory-cytokine half that those peptides don't directly address.

The "Molecular Switch" — Why a 2-Minute Half-Life Works#

The single most counterintuitive thing about ARA-290 is the pharmacokinetic profile. Plasma half-life is ~2 minutes. By any normal logic, that would be useless. But the downstream signaling cascade, once triggered, outlasts the ligand by days — the peptide essentially flips a switch and walks away.

"The plasma half-life of ARA 290 is only two minutes, yet biological effects such as tissue protection and anti-inflammatory signaling persist for days due to downstream activation of reparative pathways." — Brines M. Pharmacology & Therapeutics, 2015

This has two practical consequences. First, once-daily subcutaneous dosing is sufficient — there is no case for splitting doses or chasing steady-state plasma levels. Second, chronic continuous dosing gives diminishing returns because the reparative signaling is already saturated; community protocols converge on 4–8 week blocks with breaks rather than indefinite use.

Non-Erythropoietic Profile — No Hematocrit, No Blood Pressure#

Unlike recombinant EPO, ARA-290 does not raise hematocrit, hemoglobin, platelet count, or blood pressure. This was verified in the phase II diabetic neuropathy trial where 28 days of daily subcutaneous dosing produced no hematologic or cardiovascular shift.

"Daily subcutaneous injections of ARA 290 for 28 days resulted in significant improvement in metabolic control and neuropathic pain scores with no change in hematocrit or blood pressure." — Brines M, Dunne AN, van Velzen M, et al. Molecular Medicine, 2015

Worth being explicit: ARA-290 is not a stealth EPO analog and is not useful as an endurance or blood-boosting tool. Anyone sourcing it with that intent is working against the molecule's design. The upside is that the cardiovascular and thrombotic risks that constrain EPO use — particularly relevant in users already running AAS with elevated hematocrit — simply don't apply here.

Small-Fiber Nerve Regeneration and Clinical Outcomes#

The most validated practical output is regeneration of damaged peripheral nerve fibers. In sarcoidosis-associated small fiber neuropathy, 4 weeks of ARA-290 produced measurable symptom and quality-of-life improvements versus placebo — and follow-up work in diabetic neuropathy populations showed increases in corneal nerve fiber density, an objective anatomical endpoint rather than just subjective pain scores.

"ARA 290 was well tolerated, with no drug-related adverse events, and resulted in a statistically significant improvement in SFN symptoms and quality of life compared to placebo after 4 weeks of treatment." — Heij L, Niesters M, Swartjes M, et al. Molecular Medicine, 2012

For the physique-focused audience, the translatable use-case is not neuropathy per se but anything with a neuropathic pain or nerve-entrapment component — post-surgical paresthesias, sciatic irritation that lingers after the structural issue resolves, chemo-induced or idiopathic small-fiber symptoms, and the inflammatory/nociceptive edge that often sits on top of chronic tendinopathy. ARA-290 works on the nerve and the inflammatory milieu around it; pair it with BPC-157 and TB-500 when the underlying tissue also needs rebuilding.

Common (most users)#

• Injection-site stinging or mild erythema — the most frequently reported effect across both trials and community logs. Rotating SC sites (abdomen, flanks, outer thigh), letting bac water reach room temperature before injection, and using a fresh 29–31g insulin pin per shot handles it. If the 4mg bolus stings, splitting into two 2mg injections at separate sites usually resolves it.
• Transient mild fatigue or low-grade flu-like feeling in the first 3–7 days — reported anecdotally, self-limiting. Titration from 0.5–1mg for the first week, stepping up to 2mg, then 4mg, eliminates this for most users.
• No hematocrit shift — worth flagging as an expected non-effect. ARA-290 is engineered away from erythropoietic activity, and trials confirm hemoglobin and hematocrit do not move (Heij et al. 2012; Brines et al. 2015). A vial that pushes hematocrit is not ARA-290 — it's either contaminated or mislabeled EPO. A pre/post CBC is the cheapest QC test available.

"ARA 290 was well tolerated, with no drug-related adverse events, and resulted in a statistically significant improvement in SFN symptoms and quality of life compared to placebo after 4 weeks of treatment." — Heij et al., Molecular Medicine (2012)

Uncommon (dose-dependent or individual)#

• Escalating injection pain at 3–4mg in sensitive individuals — back off to 2mg daily or 4mg every other day; community logs describe this resolving the issue without sacrificing efficacy.
• Transient paresthesia flares in the first week of a neuropathy-focused protocol — the classic "it got worse before it got better" pattern as small fibers begin re-innervating. Not a reason to stop; expect gradual improvement over weeks 2–4.
• Mild lightheadedness immediately post-injection in a small minority — dose seated, hydrate, and the effect typically self-resolves within minutes. Not associated with any measured blood-pressure change in trials.
• No measurable impact on blood pressure, platelets, or metabolic panel at the 4mg daily × 28-day protocol, but a basic metabolic panel and CBC at baseline and end-of-cycle is cheap insurance on extended (6–8 week) runs.

"Daily subcutaneous injections of ARA 290 for 28 days resulted in significant improvement in metabolic control and neuropathic pain scores with no change in hematocrit or blood pressure." — Brines et al., Molecular Medicine (2015)

Rare but serious#

• Hypersensitivity reaction — theoretical, flagged by prudence rather than documented incidence. Warning signs: urticaria, facial swelling, wheeze, or systemic rash within minutes of injection. Discontinue immediately. More plausible with known reactivity to recombinant EPO or EPO-derived biologics.
• Unexpected hematocrit rise, thrombotic symptoms, or sudden hypertension — not a documented ARA-290 effect in any trial. If these appear, the working hypothesis is a counterfeit or contaminated vial (mislabeled EPO is the realistic failure mode given ARA-290's price point). Stop the vial, run a CBC, source from a vendor with third-party HPLC + mass spec on the specific lot.

Hard contraindications#

• Active or suspected malignancy. IRR activation is anti-apoptotic and pro-survival in injured tissue. There is no clinical data in cancer populations, and the mechanism argues against use until that data exists. Anyone with an undiagnosed mass, an unresolved cancer history, or active treatment is outside the envelope.
• Pregnancy and lactation. No reproductive toxicology data. Do not use.
• Known hypersensitivity to erythropoietin or EPO-derived peptides. Cross-reactivity is the expected failure mode.
• Do not substitute ARA-290 for EPO in any erythropoietic context — it does not raise red cell mass and will not function as a blood-boosting agent. Conversely, do not run EPO thinking ARA-290's clean safety profile transfers; it does not.

Gender, PCT, and axis considerations#

ARA-290 is non-hormonal. It does not interact with the HPG or HPT axis, does not aromatize, does not affect SHBG, prolactin, or thyroid function, and carries no virilization risk. No PCT is required regardless of cycle length. Dosing is identical across the full subject pool — the 4mg SC daily protocol is bodyweight-independent and gender-independent. Pregnancy and lactation are the only sex-specific exclusions, and they are absolute rather than dose-dependent.

"ARA 290 is a non-erythropoietic peptide that specifically targets the innate repair receptor (IRR), with clinical trials demonstrating improvement in neuropathic pain and small fiber regeneration." — van Velzen et al., Expert Opinion on Investigational Drugs (2014)